Jump to content

The Rheumatoid Arthritis Quality of Life Questionnaire

From Wikipedia, the free encyclopedia

The Rheumatoid Arthritis Quality of Life Questionnaire
Purposedetermine quality of life with Rheumatoid Arthritis

The Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL) is a disease-specific patient-reported outcome measure which determines the effect rheumatoid arthritis has on a patient's quality of life.[1] The RAQoL has 30 items with a yes and no response format[2] and takes about six minutes to complete.[1]

Scores on the RAQoL are a sum of all the individual item scores with a range from 0-30, with a lower score indicating better quality of life.[3] The RAQoL is a self-assessment questionnaire, meaning patients fill out the survey themselves in order to avoid experimental error.[4]

History

[edit]

The RAQoL was developed by Galen Research, the University of Leeds and the Academic Hospital Maastricht, and was first published in 1997.[5] It was the first patient completed quality of life questionnaire that focused on rheumatoid arthritis[6] and is distinct from other questionnaires as it includes physical contact as a dimension of quality of life.[3] Other dimensions include activities of daily living, social interaction/function, emotions, mood and recreation and pastimes.[7]

International Use

[edit]

Since its development, the RAQOL has been translated into 33 languages other than Dutch and UK English.[8] Validation studies have been performed in countries such as Sweden,[9] Argentina[10] and Australia[11] in order to confirm the responsiveness and validity of the language adaptations.

The RAQoL has been used in clinical studies in order to confirm the efficacy of proposed treatments of rheumatoid arthritis. It has been utilized in order to confirm the efficacy of tocilizumab[12][13] and infliximab.[14][15]

References

[edit]
  1. ^ a b de Jong, Z.; van der Heijde, D.; McKenna, S.P.; Whalley, D. (1997). "The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument". Rheumatology. 36 (8): 878–883. doi:10.1093/rheumatology/36.8.878. PMID 9291857. Retrieved 30 September 2013.
  2. ^ Adams, Jo; Chapman, Judith; Bradley, Sarah; Ryan, Sarah Jane (2013). "Literacy levels required to complete routinely used patient-reported outcome measures in rheumatology". Rheumatology. 52 (3): 460–464. doi:10.1093/rheumatology/kes296. PMID 23118412. Retrieved 30 September 2013.
  3. ^ a b Tijhuis, G.J.; de Jong, Z.; Zwinderman, A.H.; Zuijderduin, W.M.; Jansen, L.M.A.; Hazes, J.M.W.; Vliet Vlieland, T.P.M. (2001). "The validity of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire". Rheumatology. 40 (10): 1112–1119. doi:10.1093/rheumatology/40.10.1112. PMID 11600740. Retrieved 30 September 2013.
  4. ^ Maska, L.; Anderson, J.; Michaud, K. (November 2011). "Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL)". Arthritis Care & Research. 63 (Supplement S11): S4–S13. doi:10.1002/acr.20620. PMID 22588760.
  5. ^ Whalley, D.; McKenna, S.P.; de Jong, Z.; van der Heijde, D. (1997). "Quality of life in rheumatoid arthritis". Rheumatology. 36 (8): 884–888. doi:10.1093/rheumatology/36.8.884. PMID 9291858. Retrieved 30 September 2013.
  6. ^ Marra, Carlo A.; Woolcott, John C.; Kopec, Jacek A.; Shojania, Kamran; Offer, Robert; Brazier, John E.; Esdaile, John M.; Anis, Aslam H. (April 2005). "A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis". Social Science & Medicine. 60 (7): 1571–1582. doi:10.1016/j.socscimed.2004.08.034. PMID 15652688.
  7. ^ Lillegraven, Siri; Kvien, Tore K. (October 2007). "Measuring disability and quality of life in established rheumatoid arthritis". Best Practice & Research Clinical Rheumatology. 21 (5): 827–840. doi:10.1016/j.berh.2007.05.004. PMID 17870030.
  8. ^ "Measures Database". Galen-Research.com. Galen Research. Archived from the original on 28 January 2024. Retrieved 2 October 2013.
  9. ^ Eberhardt, Kerstin; Duckberg, Siv; Larsson, Britt-Marie; Johnson, Pia Malcus; Nived, Kerstin (July 2009). "Measuring health related quality of life in patients with rheumatoid arthritis – reliability, validity, and responsiveness of a Swedish version of RAQoL". Scandinavian Journal of Rheumatology. 31 (1): 6–12. doi:10.1080/030097402317255291. PMID 11922201. S2CID 42285569.
  10. ^ Waimann, Christian A.; Dal Pra, Fernando M.; Marengo, Maria F.; Schneeberger, Emilce E.; Gagliardi, Susana; Maldonado Cocco, Jose A.; Sanchez, Monica; Garone, A.; Chaparro del Moral, Rafael E.; Rillo, Oscar L.; Salcedo, Mariana; Rosa, Javier E.; Ceballos, F.; Soriano, Enrique R.; Citera, Gustavo (July 2012). "Quality of life of patients with rheumatoid arthritis in Argentina: reliability, validity, and sensitivity to change of a Spanish version of the Rheumatoid Arthritis Quality of Life questionnaire". Clinical Rheumatology. 31 (7): 1065–1071. doi:10.1007/s10067-013-2397-x. PMID 24158632.
  11. ^ Cox, S.R.; McWilliams, L.; Massy-Westropp, N.; Meads, D.M.; McKenna, S.P.; Proudman, S. (May 2007). "Adaptation of the RAQoL for use in Australia". Rheumatology International. 27 (7): 661–666. doi:10.1007/s00296-006-0287-0. PMID 17195065. S2CID 28105906.
  12. ^ Dougados, Maxime; Kissel, Karsten; Sheeran, Tom; Tak, Paul P.; Conaghan, Philip G.; Mola, Emilio Martin; Schett, Georg; Amital, Howard; Navarro-Sarabia, Federico; Hou, Antony; Bernasconi, Corrado; Huizinga, TWJ (2013). "Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)". Annals of the Rheumatic Diseases. 72 (1): 43–50. doi:10.1136/annrheumdis-2011-201282. PMC 3551223. PMID 22562983.
  13. ^ Fahy, Sarah. "Efficacy of tocilizumab in patients with rheumatoid arthritis". Current Controlled Trials. doi:10.1186/ISRCTN21216199. Retrieved 2 October 2013.
  14. ^ Quinn, Mark A.; Conaghan, Philip G.; O'Connor, Philip J.; Karim, Zunaid; Greenstein, Adam; Brown, Andrew; Brown, Clare; Fraser, Alexander; Jarret, Stephen; Emery, Paul (January 2005). "Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial". Arthritis & Rheumatism. 52 (1): 27–35. doi:10.1002/art.20712. PMID 15641102.
  15. ^ Bejarano, Victoria; Conaghan, Philip G.; Quinn, Mark A.; Saleem, Benazir; Emery, Paul (2010). "Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis". Rheumatology. 49 (10): 1971–1974. doi:10.1093/rheumatology/keq194. PMID 20595536. Retrieved 2 October 2013.
Retrieved from "https://wiki.riteme.site/w/index.php?title=The_Rheumatoid_Arthritis_Quality_of_Life_Questionnaire&oldid=1264109465"